CD274 and autoimmune disease: Additionally, certain patient characteristics that were excluded from the Keynote-024 trial were represented within the real-world population, including patients who had ECOG PS > 1 (27%), a history of autoimmune disease(s) (12%), active brain metastases (5%), a PD-L1 expression below 50% (17%), or stage IIIB/C disease at diagnosis (11%).